[4,8\'\':4\'\',8\'\'\'\'-Terflavan]-3,3\'\',3\'\'\'\',4\',4\'\'\',4\'\'\'\',4\'\'\'\'\',5,5\'\',5\'\'\'\',7,7\'\',7\'\'\'\'-tridecol



Compound IDCDAMM01287
Common name[4,8\'\':4\'\',8\'\'\'\'-Terflavan]-3,3\'\',3\'\'\'\',4\',4\'\'\',4\'\'\'\',4\'\'\'\'\',5,5\'\',5\'\'\'\',7,7\'\',7\'\'\'\'-tridecol
IUPAC name2-(4-hydroxyphenyl)-8-[3,5,7-trihydroxy-2-(4-hydroxyphenyl)-8-[3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]-3,4-dihydro-2H-chromen-4-yl]-3,4-dihydro-2H-chromene-3,4,5,7-tetrol
Molecular formulaC45H38O16

Experimental data

Retention time17.71
Adduct[M+Na]+
Actual mz857.211
Theoretical mz857.205
Error7.21
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score5.2542

Identifiers and class information

Inchi keyPXMVHFKJSCHILV-UHFFFAOYNA-N
SmilesOC1=CC=C(C=C1)C2OC=3C=C(O)C=C(O)C3C(C4=C(O)C=C(O)C5=C4OC(C6=CC=C(O)C=C6)C(O)C5C=7C(O)=CC(O)=C8C7OC(C9=CC=C(O)C=C9)C(O)C8O)C2O
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)10
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)13
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)834.786
Computed dipole moment(dipole)8.966
Total solvent accessible surface area (SASA)992.685
Hydrophobic component of SASA (FOSA)75.103
Hydrophilic component of SASA (FISA)470.867
Pie component of the SASA (PISA)446.715
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2103.09
Number of hydrogen bond donors (donorHB)13
Number of hydrogen bond acceptors (accptHB)15.8
Free energy of solvation of dipole (dip^2/V)0.0382212
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0573875
Globularity descriptor (glob)0.799698
Predicted polarizability in cubic angstroms (QPpolrz)73.931
Predicted hexadecane/gas partition coefficient (QPlogPC16)26.681
Predicted octanol/gas partition coefficient (QPlogPoct)55.064
Predicted water/gas partition coefficient (QPlogPw)40.085
Predicted octanol/water partition coefficient (QPlogPo/w)1.232
Predicted aqueous solubility (QPlogS)-5.155
Conformation-independent predicted aqueous solubility (CIQPlogS)-10.762
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.903
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.339
Predicted brain/blood partition coefficient (QPlogBB)-5.129
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.088
Predicted skin permeability, log Kp (QPlogKp)-7.376
PM3 calculated ionization potential (IP(ev))8.583
PM3 calculated electron affinity (EA(eV))-0.091
Number of likely metabolic reactions (#metab)18
Prediction of binding to human serum albumin (QPlogKhsa)0.031
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)285.217
Number of nitrogen and oxygen atoms (#NandO)16
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)2

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
Q92731ESR2Estrogen receptor betaT80896SEA
P03372ESR1Estrogen receptor alphaT02506SEA
P20151KLK2Kallikrein 2T01908SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P49763PGFPlacenta growth factorT70792SEA
P52209PGD6-phosphogluconate dehydrogenaseT76497SEA
P16152CBR1Carbonyl reductase [NADPH] 1T70518SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T80896DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q92731ESR2
T80896DI0108Cushing syndrome[ICD-11: 5A70]Q92731ESR2
T80896DI0254Menopausal disorder[ICD-11: GA30]Q92731ESR2
T80896DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q92731ESR2
T02506DI0106COVID-19[ICD-11: 1D6Y]P03372ESR1
T01908DI0213Innate/adaptive immunodeficiency[ICD-11: 4A00]P20151KLK2
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T70792DI0095Colorectal cancer[ICD-11: 2B91]P49763PGF
T76497DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P52209PGD
T70518DI0037Asthma[ICD-11: CA23]P16152CBR1

Copyright © 2025